Dong Ik Cha1, Kyoung Doo Song1, Sang Yun Ha2, Jung Yong Hong3, Jeong Ah Hwang1, Seong Eun Ko1. 1. Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
OBJECTIVES: To report the long-term follow-up data including computed tomography (CT) findings of oxaliplatin-induced liver damage in patients with colorectal cancer. METHODS: Three hundred and fifty-six patients who underwent surgery followed by oxaliplatin-based chemotherapy (OBC) for colorectal cancer between January 2013 and December 2014 were included. Abdominal CT images and laboratory results (serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total bilirubin, and platelet counts) were reviewed immediately before (as baseline), during, and after adjuvant OBC. Abdominal CT images were reviewed to assess the heterogeneous liver parenchyma, increase in size of the spleen, development of acute portosystemic shunts during OBC, and imaging findings of chronic portal hypertension. RESULTS: During OBC, 90.2% (321/356) of the patients developed parenchymal heterogeneity. Increase in the spleen size during the OBC period was seen in 62.4% (225/356) of patients. The overall rate of development of acute portosystemic shunts during OBC was 23.9% (85/356). These findings were resolved after cessation of OBC except in 1.4% (5/356) of the patients in whom chronic portal hypertension persisted even after completion of OBC. Serum AST, ALT, and total bilirubin levels increased and platelet counts decreased during OBC and returned to normal after completion of OBC; however, they did not reach the pre-OBC levels. CONCLUSION: Although most changes associated with liver damage reversed to normal range after completion of OBC, some parameters did not reverse to the pretreatment level, and chronic portal hypertension developed in a small number of patients. ADVANCES IN KNOWLEDGE: Chronic, persistent oxaliplatin-induced liver damage was not an infrequent complication after oxaliplatin-based chemotherapy for patients with colorectal cancer. It may cause non-cirrhotic portal hypertension and associated complications such as variceal bleeding.
OBJECTIVES: To report the long-term follow-up data including computed tomography (CT) findings of oxaliplatin-induced liver damage in patients with colorectal cancer. METHODS: Three hundred and fifty-six patients who underwent surgery followed by oxaliplatin-based chemotherapy (OBC) for colorectal cancer between January 2013 and December 2014 were included. Abdominal CT images and laboratory results (serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total bilirubin, and platelet counts) were reviewed immediately before (as baseline), during, and after adjuvant OBC. Abdominal CT images were reviewed to assess the heterogeneous liver parenchyma, increase in size of the spleen, development of acute portosystemic shunts during OBC, and imaging findings of chronic portal hypertension. RESULTS: During OBC, 90.2% (321/356) of the patients developed parenchymal heterogeneity. Increase in the spleen size during the OBC period was seen in 62.4% (225/356) of patients. The overall rate of development of acute portosystemic shunts during OBC was 23.9% (85/356). These findings were resolved after cessation of OBC except in 1.4% (5/356) of the patients in whom chronic portal hypertension persisted even after completion of OBC. Serum AST, ALT, and total bilirubin levels increased and platelet counts decreased during OBC and returned to normal after completion of OBC; however, they did not reach the pre-OBC levels. CONCLUSION: Although most changes associated with liver damage reversed to normal range after completion of OBC, some parameters did not reverse to the pretreatment level, and chronic portal hypertension developed in a small number of patients. ADVANCES IN KNOWLEDGE: Chronic, persistent oxaliplatin-induced liver damage was not an infrequent complication after oxaliplatin-based chemotherapy for patients with colorectal cancer. It may cause non-cirrhotic portal hypertension and associated complications such as variceal bleeding.
Authors: Na Yeon Han; Beom Jin Park; Kyung Sook Yang; Min Ju Kim; Deuk Jae Sung; Ki Choon Sim; Sung Bum Cho Journal: AJR Am J Roentgenol Date: 2017-08-16 Impact factor: 3.959
Authors: Michael J Overman; Dipen M Maru; Chusilp Charnsangavej; Evelyn M Loyer; Huamin Wang; Priyanka Pathak; Cathy Eng; Paulo M Hoff; Jean-Nicolas Vauthey; Robert A Wolff; Scott Kopetz Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: N N Mehta; R Ravikumar; C A Coldham; J A C Buckels; S G Hubscher; S R Bramhall; S J Wigmore; A D Mayer; D F Mirza Journal: Eur J Surg Oncol Date: 2007-12-21 Impact factor: 4.424
Authors: Brian R Curtis; James Kaliszewski; Marisa B Marques; M Wasif Saif; Lisle Nabelle; Jules Blank; Janice G McFarland; Richard H Aster Journal: Am J Hematol Date: 2006-03 Impact factor: 10.047
Authors: Julian H Slade; Mona L Alattar; David R Fogelman; Michael J Overman; Atin Agarwal; Dipen M Maru; Ryanne L Coulson; Chusilp Charnsangavej; J Nicolas Vauthey; Robert A Wolff; Scott Kopetz Journal: Clin Colorectal Cancer Date: 2009-10 Impact factor: 4.481
Authors: L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321